Mel Krajden

23.4k total citations · 1 hit paper
367 papers, 11.8k citations indexed

About

Mel Krajden is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Mel Krajden has authored 367 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 276 papers in Epidemiology, 153 papers in Hepatology and 102 papers in Infectious Diseases. Recurrent topics in Mel Krajden's work include Hepatitis C virus research (145 papers), Hepatitis B Virus Studies (126 papers) and Liver Disease Diagnosis and Treatment (90 papers). Mel Krajden is often cited by papers focused on Hepatitis C virus research (145 papers), Hepatitis B Virus Studies (126 papers) and Liver Disease Diagnosis and Treatment (90 papers). Mel Krajden collaborates with scholars based in Canada, United States and Australia. Mel Krajden's co-authors include Danuta M. Skowronski, Martin Petric, Gina Ogilvie, Naveed Z. Janjua, Darrel Cook, Mark Tyndall, Jason Grebely, Mark Gilbert, Gaston De Serres and Nathalie Bastien and has published in prestigious journals such as New England Journal of Medicine, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Mel Krajden

356 papers receiving 11.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of Severe Acute Respiratory Syndrome in Canada

2003 867 citations Bonnie Henry, Danuta M. Skowronski et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Mel Krajden	8.4k	3.5k	3.5k	881	871	367	11.8k
Yong Poovorawan	8.2k 1.0×	6.0k 1.7×	4.3k 1.2×	1.1k 1.3×	1.8k 2.0×	763	15.4k
Beth P. Bell	7.0k 0.8×	4.3k 1.2×	6.7k 1.9×	561 0.6×	1.0k 1.1×	135	13.2k
Graham Cooke	4.4k 0.5×	4.1k 1.2×	2.6k 0.7×	758 0.9×	500 0.6×	188	9.1k
Laith J. Abu‐Raddad	5.8k 0.7×	4.4k 1.2×	2.1k 0.6×	784 0.9×	528 0.6×	299	11.7k
Arnaud Fontanet	4.8k 0.6×	6.2k 1.7×	1.9k 0.5×	427 0.5×	780 0.9×	272	12.2k
Anthony E. Fiore	7.5k 0.9×	2.5k 0.7×	2.7k 0.8×	447 0.5×	690 0.8×	91	10.9k
Pierre Van Damme	9.9k 1.2×	5.4k 1.5×	5.6k 1.6×	681 0.8×	884 1.0×	563	16.7k
Lyn Finelli	10.0k 1.2×	3.3k 0.9×	4.0k 1.2×	266 0.3×	478 0.5×	179	14.0k
Gregory L. Armstrong	5.1k 0.6×	2.2k 0.6×	4.3k 1.2×	249 0.3×	755 0.9×	61	8.7k
Yazdan Yazdanpanah	3.8k 0.5×	6.6k 1.9×	1.3k 0.4×	1.0k 1.1×	716 0.8×	362	11.3k

Countries citing papers authored by Mel Krajden

Since Specialization

Citations

This map shows the geographic impact of Mel Krajden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mel Krajden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mel Krajden more than expected).

Fields of papers citing papers by Mel Krajden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mel Krajden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mel Krajden. The network helps show where Mel Krajden may publish in the future.

Co-authorship network of co-authors of Mel Krajden

This figure shows the co-authorship network connecting the top 25 collaborators of Mel Krajden. A scholar is included among the top collaborators of Mel Krajden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mel Krajden. Mel Krajden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krajden, Mel, et al.. (2024). Expanding access to healthcare for people who use drugs and sex workers: hepatitis C elimination implications from a qualitative study of healthcare experiences in British Columbia, Canada. Harm Reduction Journal. 21(1). 75–75. 2 indexed citations

Makuza, Jean Damascène, Dahn Jeong, Stanley Wong, et al.. (2024). Association of hepatitis B virus treatment with all-cause and liver-related mortality among individuals with HBV and cirrhosis: a population-based cohort study. The Lancet Regional Health - Americas. 36. 100826–100826. 2 indexed citations

Morrow, Richard L., Mawuena Binka, Sofia Bartlett, et al.. (2024). Impact of the COVID-19 Pandemic on Hepatitis C Treatment Initiation in British Columbia, Canada: An Interrupted Time Series Study. Viruses. 16(5). 655–655. 2 indexed citations

Caya, Chelsea, Matthew P. Cheng, Karen Colwill, et al.. (2023). Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID‐19 serological assays as a proof of concept. Vox Sanguinis. 118(12). 1069–1077. 2 indexed citations

Morshed, Muhammad, et al.. (2023). Clinical utility and interpretive guidance for SARS-CoV-2 serological testing. Clinical Microbiology Newsletter. 45(24). 209–218.

Gottschlich, Anna, Lovedeep Gondara, Laurie Smith, et al.. (2023). Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study. The Lancet Regional Health - Americas. 26. 100598–100598. 3 indexed citations

Skowronski, Danuta M., Solmaz Setayeshgar, Macy Zou, et al.. (2022). Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada. The Journal of Infectious Diseases. 226(3). 485–496. 7 indexed citations

Morshed, Muhammad, Min-Kuang Lee, Darrel Cook, et al.. (2022). British Columbia’s Experience after Implementation of the Treponema pallidum Reverse Algorithm and PCR Detection, 2015 to 2020. Microbiology Spectrum. 10(3). e0068622–e0068622. 5 indexed citations

Makuza, Jean Damascène, Dahn Jeong, Mawuena Binka, et al.. (2022). Impact of Hepatitis B Virus Infection, Non-alcoholic Fatty Liver Disease, and Hepatitis C Virus Co-infection on Liver-Related Death among People Tested for Hepatitis B Virus in British Columbia: Results from a Large Longitudinal Population-Based Cohort Study. Viruses. 14(11). 2579–2579. 5 indexed citations

10.

Nasreen, Sharifa, Héctor Alexander Velásquez García, Geng Zhang, et al.. (2022). Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study. Clinical Infectious Diseases. 76(4). 640–648. 8 indexed citations

11.

Skowronski, Danuta M., Solmaz Setayeshgar, Macy Zou, et al.. (2021). Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada. Clinical Infectious Diseases. 74(7). 1158–1165. 35 indexed citations

12.

Janjua, Naveed Z., Stanley Wong, Dahn Jeong, et al.. (2021). Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. Journal of Hepatology. 75(5). 1049–1057. 38 indexed citations

13.

Wilton, James, Mei Chong, Mohammad Ehsanul Karim, et al.. (2021). Prescription opioid treatment for non-cancer pain and initiation of injection drug use: large retrospective cohort study. BMJ. 375. e066965–e066965. 17 indexed citations

14.

Wilton, James, Stanley Wong, Amanda Yu, et al.. (2020). Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study. Open Forum Infectious Diseases. 7(3). ofaa055–ofaa055. 26 indexed citations

15.

Gottschlich, Anna, Dirk van Niekerk, Laurie Smith, et al.. (2020). Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort. Cancer Epidemiology Biomarkers & Prevention. 30(1). 22–29. 16 indexed citations

16.

Janjua, Naveed Z., Stanley Wong, Maryam Darvishian, et al.. (2020). The impact of SVR from direct‐acting antiviral‐ and interferon‐based treatments for HCV on hepatocellular carcinoma risk. Journal of Viral Hepatitis. 27(8). 781–793. 37 indexed citations

17.

Janjua, Naveed Z., Maryam Darvishian, Stanley Wong, et al.. (2019). Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy. Hepatology Communications. 3(4). 478–492. 22 indexed citations

18.

Cook, Darrel, Laurie Smith, Jennifer Law, et al.. (2018). Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial. Journal of Clinical Virology. 108. 32–37. 15 indexed citations

19.

Alavi, Maryam, Naveed Z. Janjua, Mei Chong, et al.. (2017). Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. Journal of Viral Hepatitis. 25(5). 473–481. 15 indexed citations

20.

Jacka, Brendan, Bethany C. Bray, Tanya Applegate, et al.. (2017). Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach. Journal of Viral Hepatitis. 25(1). 28–36. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact